• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging).

作者信息

Owen Roger G

机构信息

St James's Institute of Oncology, Leeds, United Kingdom.

出版信息

Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000243. eCollection 2019 Jun.

DOI:10.1097/HS9.0000000000000243
PMID:35309827
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8925697/
Abstract
摘要

相似文献

1
Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging).多发性骨髓瘤中的微小残留病（mrd）：预后及治疗意义（包括影像学）
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000243. eCollection 2019 Jun.
2
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.多发性骨髓瘤患者完全缓解后的纵向微小残留病灶评估——来自 EMN02/HO95 MM 试验中 NMSG 流式微小残留病灶子研究的结果。
BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1.
3
Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.多发性骨髓瘤的治疗评估和微小残留病灶检测的功能成像。
Int J Mol Sci. 2020 Jul 29;21(15):5406. doi: 10.3390/ijms21155406.
4
Minimal residual disease in multiple myeloma: current status.多发性骨髓瘤中的微小残留病：现状
Biomark Res. 2021 Oct 14;9(1):75. doi: 10.1186/s40364-021-00328-2.
5
[Impact of minimal residual disease detection after treatment of multiple myeloma].[多发性骨髓瘤治疗后微小残留病检测的影响]
Orv Hetil. 2019 Mar;160(13):502-508. doi: 10.1556/650.2019.31353.
6
Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches.多发性骨髓瘤中的微小残留病：免疫治疗方法的现状与未来应用
Front Oncol. 2020 May 27;10:860. doi: 10.3389/fonc.2020.00860. eCollection 2020.
7
Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.多参数流式细胞术评估多发性骨髓瘤微小残留病
Klin Onkol. 2017 Summer;30(Supplementum2):21-28. doi: 10.14735/amko20172S21.
8
[Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].[多参数流式细胞术检测微小残留病在新诊断多发性骨髓瘤中的作用：106例患者分析]
Zhonghua Xue Ye Xue Za Zhi. 2018 May 14;39(5):376-381. doi: 10.3760/cma.j.issn.0253-2727.2018.05.006.
9
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.微小残留病灶检测在多发性骨髓瘤治疗选择和药物研发中的作用：当前价值与未来应用。
Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.
10
Multiple Myeloma Minimal Residual Disease.多发性骨髓瘤微小残留病
Cancer Treat Res. 2016;169:103-122. doi: 10.1007/978-3-319-40320-5_7.

引用本文的文献

1
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options.多发性骨髓瘤：治疗选择数量迅速增加带来的预后改善
Target Oncol. 2025 Mar;20(2):247-267. doi: 10.1007/s11523-024-01122-4. Epub 2025 Jan 29.

本文引用的文献

1
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.流式细胞术与功能成像相结合，用于监测骨髓瘤的残留疾病。
Leukemia. 2019 Jul;33(7):1713-1722. doi: 10.1038/s41375-018-0329-0. Epub 2018 Dec 20.
2
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.采用流式细胞术和等位基因特异性寡核苷酸实时定量聚合酶链反应检测接受来那度胺维持治疗的骨髓瘤患者的微小残留病：一项汇总分析。
Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18.
3
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.流式细胞术在系统性轻链淀粉样变中的快速筛选和自动风险评估中的应用。
Leukemia. 2019 May;33(5):1256-1267. doi: 10.1038/s41375-018-0308-5. Epub 2018 Dec 12.
4
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.深度测序检测微小残留病灶阴性是多发性骨髓瘤的一个主要预后因素。
Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.
5
Daratumumab plus bortezomib and dexamethasone bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.达雷妥尤单抗联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤：CASTOR 更新分析。
Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.
6
Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.达雷妥尤单抗联合来那度胺和地塞米松 vs. 来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤：POLLUX 更新分析。
Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.
7
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.多发性骨髓瘤中的微小残留病检测：MSKCC 10色单管法与EuroFlow 8色双管法的比较
Blood Adv. 2017 May 3;1(12):728-732. doi: 10.1182/bloodadvances.2016003715. eCollection 2017 May 9.
8
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.多发性骨髓瘤的缓解深度：三项PETHEMA/GEM临床试验的汇总分析
J Clin Oncol. 2017 Sep 1;35(25):2900-2910. doi: 10.1200/JCO.2016.69.2517. Epub 2017 May 12.
9
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.用于高灵敏度和标准化检测多发性骨髓瘤微小残留病的新一代流式检测技术。
Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.
10
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.微小残留病与多发性骨髓瘤患者更好的生存结果的关联：一项荟萃分析。
JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.